


	page
Board of directors, management and administration	1
Directors' report	2
Report of the auditors to the members of AMREF	3
Income statement	4
Balance sheet	5
Statement of changes in reserves/funds	6
Cash flow statement	7
Accounting policies	8-9
Notes forming part of the financial statements	10-15
Sources of funding	16
Expenditure by country	17
Expenditure by programme	18
Analysis of expenditure	19
Grant funds received by country	20
Analysis of grants received by country	21
AMREF international offices	22





Board of Directors

Mr. Bethuel Kiplagat (Chairman)
Dr. John Batten (Director General)
Dr. Fred Binka
Mr. Robert Bird
Mr. Bruce Bodner
Dr. Irwin Friedman
Mr. Francis Howard
Dr. Jessica Jitta
Dr. Adanetch Kidanemariam
Dr. Eunice Kiereini
Dr. Adeline Kimambo
Dr. Ulrich Laukamm-Josten
Dr. John Nixon
Mrs. Isabella Ocholla Wilson
Mr. Hans Tuyt
Dr. Alfonso Villalonga

Management

Dr. J. Batten: Director General
Dr. D. Bukenya: Tanzania Country Director
Ms. L. Elliott: Director of Training & Human Resources
Ms. M. Kjaer: Kenya Country Director
Dr. P. Ngatia: Uganda Country Director

Dr. V. Nantulya: Director of Programmes (To 15 Jan 2001)
Mr. W. Okedi: South Africa Country Director (To 4 Feb 2001)
Mr. V. S. Thyagarajan: Finance & Administration Director (Since 18 Sept. 2000)
Mr. C. Williams: Director of Information & Resource Mobilization
Dr. P. Youri: Director of Extension

Company Secretary

Mr. V. S. Thyagarajan (Acting)

Bankers

Barclays Bank of Kenya Ltd
ABN AMRO - Nairobi

Lawyers

Kaplan & Stratton

Registered Office & Headquarters

African Medical & Research Foundation,
P. O. Box 30125, Nairobi. Tel: 254 02 501301, 500508.
E mail: amrefinf@africaonline.co.ke Telex: 23254 AMREF
Faxes: 254 02 609518 (main), 609522 (finance and administration)

1. The directors submit their report together with the audited financial statements for the year ended 30 September 2000 which disclose the state of affairs of the company.

2. **OBJECTIVES OF THE FOUNDATION**

The mission of AMREF is to improve the health of disadvantaged people of Africa. The strategic objectives for addressing the mission are to develop, test and promote the adoption of appropriate models for improving health, to contribute to capacity development at all levels for sustainable health action and to contribute to the development of an enabling environment for health improvement.

3. **RESULTS**

Recurrent expenditure of the Foundation amounted to US\$ 18.3 million in 1999-2000 (US\$15.4 million in 1998-1999).

4. **DIRECTORS**

- 4.1 The directors who held office during the year and to the date of this report were:

Mr. Bethuel Kiplagat	Mr. Robert Bird
Dr. John Batten	Dr. Eunice Kiereini
Mrs Isabella Ochola-Wilson	Dr. Alfonso Villalonga
Mr. Bruce Bodner	Dr. Adanetch Kidanemariam
Mr Francis Howard	Dr. Fred Binka
Dr. John Nixon	Dr. Jessica Jitta
Mr. Hans Tuyt	Dr. Adeline Kimambo
Dr. Ulrich Laukamm-Josten	
Dr. Irwin Friedman	

- 4.2 The following Directors retiring by rotation at the AGM held on 10 March 2000, and, being eligible, were re-elected at the same meeting:

Mr. Bethuel Kiplagat
Mrs Isabella Ochola-Wilson
Mr. Bruce Bodner
Mr. Francis Howard

- 4.3 One of the directors, Mr. Bo Karlstrom, retired with effect from 10 March 2000.

5. **AUDITORS**

The company's auditors, PricewaterhouseCoopers, continue in office in accordance with Section 159(2) of the Companies Act.

By order of the Board



V.S. Thyagarajan, Company Secretary (Acting)
8 February 2001

1. We have audited the financial statements set out on pages 4 to 15. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit. The financial statements are in agreement with the books of account.

2. Respective responsibilities of directors and auditors

The directors are responsible for the preparation of financial statements which give a true and fair view of the company's state of affairs and its net surplus or deficit. Our responsibility is to express an independent opinion on the financial statements based on our audit and to report our opinion to you.

3. Basis of opinion

We conducted our audit in accordance with International Standards on Auditing. Those standards require that we plan and perform our audit to obtain reasonable assurance that the financial statements are free from material misstatement. An audit includes an examination, on a test basis, of evidence supporting the amounts and disclosures in the financial statements. It also includes an assessment of the accounting policies used and significant estimates made by the directors, as well as an evaluation of the overall presentation of the financial statements.

4. Opinion

In our opinion proper books of account have been kept and the financial statements give a true and fair view of the state of the company's financial affairs at 30 September 2000 and of its surplus and cash flows for the year then ended and comply with International Accounting Standards and the Kenyan Companies Act.



PricewaterhouseCoopers
Certified Public Accountants
Nairobi, 1 March 2001

	Notes	2000 US\$'000	1999 US\$'000
INCOME			
Grants restricted	1	13,938	11,035
Grants - unrestricted	1	2,295	2,206
Interest and gains on deposits	6a	179	126
Other income	2	<u>2,410</u>	<u>1,689</u>
Total income		<u><u>18,822</u></u>	<u><u>15,056</u></u>
EXPENDITURE			
Direct Programme activity		14,999	12,155
Programme monitoring and support	3a	1,039	1,275
Institutional development	3b	718	562
Administration		1,380	1,201
Finance	6b	<u>209</u>	<u>206</u>
Total Expenses		<u><u>18,345</u></u>	<u><u>15,399</u></u>
Surplus/(Deficit) for the year		<u><u>477</u></u>	<u><u>(343)</u></u>

	Notes	2000 US\$'000	1999 US\$'000
FUNDS EMPLOYED			
Capital Reserves	7	4,194	3,343
General Reserves	8	286	(366)
Endowment fund	9	375	375
Other funds	10	77	77
Total funds		<u>4,932</u>	<u>3,429</u>
REPRESENTED BY			
Non-current assets			
Fixed Assets	12	4,194	3,343
Investments	13	1,424	525
		5,618	3,868
Current assets			
Stocks	14	419	443
Debtors and Prepayments	15	787	670
Grant income receivable		2,443	2,361
Cash and cash equivalents	16	2,400	3,037
		6,049	6,511
Current liabilities			
Creditors and other payables	17	2,116	1,763
Provision for liabilities and charges	11	282	203
Grants unexpended		4,337	4,937
Bank loan		-	47
		6,735	6,950
Net current assets/(liabilities)		<u>(686)</u>	<u>(439)</u>
Total Assets		<u>4,932</u>	<u>3,429</u>

The financial statements on pages 4 to 15 were approved by the board of directors on 1 March 2001 for issue and signed on its behalf by:



John R Batten, *Director General*



Bethuel Kiplagat, *Chairman*

	General Reserves US\$'000	Endowment Fund US\$'000	Other Funds US\$'000	Capital Reserves US\$'000	Total US\$'000
Balance at 1 October 1998	(59)	360	108	2,418	2,827
Prior year adjustment					
Adoption of IAS 19	<u>(150)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(150)</u>
As restated	(209)	360	108	2,418	2,677
Deficit for the year	(343)	-	-	-	(343)
Transfers during the year	186	-	-	(186)	-
Additions during the year	-	15	-	1,111	1,126
Reduction during the year	<u>-</u>	<u>-</u>	<u>(31)</u>	<u>-</u>	<u>(31)</u>
Balance as at 30 September 1999	<u>(366)</u>	<u>375</u>	<u>77</u>	<u>3,343</u>	<u>3,429</u>
Balance as at 1 October 1999	(366)	375	77	3,343	3,429
Surplus for the year	477	-	-	-	477
Transfers during the year	175	-	-	(175)	-
Additions during the year	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,026</u>	<u>1,026</u>
Balance as at 30 September 2000	<u><u>286</u></u>	<u><u>375</u></u>	<u><u>77</u></u>	<u><u>4,194</u></u>	<u><u>4,932</u></u>

Prior year adjustment relates to accrued expenses of US\$150,000 towards employee entitlement for annual leave as permitted by company rules & regulations, as required by IAS 19.

	Notes	2000 US\$'000	1999 US\$'000
Cash flows from operating activities			
Grants received	1	16,624	12,671
Other Cash receipts	2	2,410	1,689
Cash paid to suppliers and employees		(18,032)	(14,302)
Depreciation	12	175	185
Interest paid		<u>(21)</u>	<u>(25)</u>
Net cash from operating activities		1,156	218
Cash flow from investing activities			
Payments to acquire fixed assets	12	(1,026)	(1,111)
Reduction in investments		-	155
Payment for additional investments		(899)	(165)
Interest received		<u>179</u>	<u>126</u>
Net cash used in investing activities		(1,746)	(995)
Cash flows from financial activities			
Increase in Endowment Fund		-	15
Reduction in other funds		<u>-</u>	<u>(31)</u>
Cash from finance activities		<u>-</u>	<u>(16)</u>
Net (Decrease)/increase in cash and cash equivalents		(590)	(793)
Cash and cash equivalents at beginning of the year	16	<u>2,990</u>	<u>3,783</u>
Cash and cash equivalents at end of the year		<u><u>2,400</u></u>	<u><u>2,990</u></u>

The principal accounting policies adopted in the preparation of these financial statements are set out below:

a Basis of preparation

The financial statements are prepared in accordance with and comply with International Accounting Standards, which have been adopted with effect from 1 October 1999.

The financial statements are prepared under the historical cost convention.

b Grant income

This represents donations received and receivable in respect of project expenditure incurred during the year

- i. Expenditure incurred on projects for which a donation has not been received by the year-end and for which there are commitments from donors is carried forward as grant income receivable.
- ii. Grants and donations received in advance of the related project expenditure are not taken as income but recorded as creditors (grants unexpended) at the year end and carried forward for utilization in the following year.
- iii. The value of small gifts (e.g. medicines) and some personnel costs from local and overseas donors is not reflected in the accounts.

c Foreign Currency

- i. Transactions in currencies other than US dollars (other currencies) are converted to base currency (US dollars) using the exchange rate of the mid of the month when the transactions took place.
- ii. At the balance sheet date assets and liabilities held in other currencies are converted to US dollars using the exchange rates then ruling.
- iii. Exchange gains or losses arising during the course of the year are taken up in the income and expenditure account.

d Investments

Non current investments, excluding marketable securities, are shown at cost and provision is only made where, in the opinion of the Directors, there is a permanent diminution in value. Where there has been a permanent diminution in the value of an investment, it is recognised as an expense in the period in which the diminution is identified.

e Fixed Assets

- i. Assets donated to the Foundation are included in the accounts at a valuation, which is an approximation of cost, as estimated by management. Fixed assets purchased for donor-funded health programmes are expensed in the year of purchase. All other fixed assets are stated in the account at cost.

- ii. Depreciation is calculated on the straight line basis to write down the cost of each asset, or the revalued amounts, to their residual values over their estimated useful life as follows:

Buildings	5%
Aircraft	5% - 12.5%
Motor vehicles, medical, surgical and radio equipment	25%
Furniture, fittings and general equipment	12.5%

- iii. Gains and losses on disposal of property, plant and equipment are determined by reference to their carrying amount and are taken into account in determining operating income.

f Stocks

- i. Stocks and work in progress are valued at the lower of cost and net realisable value. Cost is determined using the first-in, first-out cost method.
- ii. Provision is made for obsolete and defective stocks

g Receivables/Debtors

Trade receivables are carried at anticipated realisable value. An estimate is made for doubtful receivables based on a review of all outstanding amounts at the year-end. Bad debts are written off in the year in which they are identified.

h Employee Benefits

The estimated liability for employees' accrued annual leave entitlement at the balance sheet date is an expense accrual.

i Aircraft Maintenance

Provision is made to cover the estimated cost of major overhaul of aircraft on the basis of hours flown.

j Pension obligations

The company operates a defined contribution pension scheme for all its local employees. The scheme is administered by an insurance company and is funded from contributions from both the company and employees where applicable. In respect of employees on international contract, the company contributes to individual pension schemes chosen by the staff concerned.

The company's contributions of 14% of basic pay to the defined contribution pension scheme and the individual pension schemes are charged to the Income and Expenditure account in the year to which they relate.

k Cash and cash equivalents

For the purposes of the cash flow statement, cash and cash equivalents comprise cash in hand, deposits held at call with banks, and investments in money market instruments, net of bank overdrafts.

l Capital Fund

The Capital fund has been created to reflect the amounts donated for and monies spent on capital expenditure. The Fund is adjusted through the general fund to reflect movements in fixed assets for acquisition, depreciation and disposals such that the capital fund is equivalent to the net book amount of the fixed assets it represents.

m Comparatives

Where necessary, comparative figures have been adjusted to conform with changes in presentation in the current year. In particular, the comparatives have been adjusted or extended to take into account the requirements of International Accounting Standards which the company has implemented in the year ended 30 September 2000

1 Grant Funds

	Restricted Funds US\$'000	2000 Unrestricted Funds US\$'000	Total Funds US\$'000	1999 Total Funds US\$'000
Grant received	12,933	3,691	16,624	12,671
Opening balance b/fwd	2,539	37	2,576	3,858
Closing balance c/fwd	<u>(800)</u>	<u>(1,094)</u>	<u>(1,894)</u>	<u>(2,576)</u>
	14,672	2,634	17,306	13,953
Amount transferred to capital fund	(687)	(339)	(1,026)	(1,111)
Amount transferred to/(from) grant funds	<u>(47)</u>	<u>-</u>	<u>(47)</u>	<u>399</u>
Grants treated as income for the year	<u>13,938</u>	<u>2,295</u>	<u>16,233</u>	<u>13,241</u>

2 Other income

Income from Air Ambulance recoveries			1,771	977
Other Income			<u>639</u>	<u>712</u>
			<u>2,410</u>	<u>1,689</u>

- 3 a) Programme monitoring and support costs relate to building institutional capacity to develop, design, manage, monitor, evaluate, document and share programme and project experiences. They also include development of database for monitoring technical and budget performance against project targets/milestones.
- b) The institutional development costs relate to building and maintaining institutional capacity for governance, management and mobilisation of resources, human resource development and building networks and partnerships.

	2000	1999
	US\$'000	US\$'000
4 Operating surplus		
The following items have been charged in arriving at surplus/(deficit) for the year		
Depreciation on property, plant and equipment (note 12)	175	185
Staff costs (note 5)	6,890	6,181
Auditors' remuneration	14	12
Directors' remuneration		
- expenses reimbursed to Directors	66	67
- fees	-	-
- other	<u>125</u>	<u>117</u>
5 Staff costs		
The following items are included within staff costs:		
Termination benefits	2	5
Pension costs (defined contribution plans)	717	606
The number of persons employed by the company at the year end was:	<u>554</u>	<u>538</u>
6 Finance costs/income		
a) Income:	<u>179</u>	<u>126</u>
Interest and gains on deposits	<u>179</u>	<u>126</u>
b) Costs:		
Interest paid	21	25
Bank charges	44	43
Net foreign exchange (gains)/losses	<u>144</u>	<u>138</u>
	<u>209</u>	<u>206</u>

	2000 US\$'000	1999 US\$'000
7 Capital Reserves		
Movements in the capital fund were as follows		
Balance at 1 October 1999	3,343	2,418
Add: Additional Grants received during the year	1,026	1,111
Add: Transfer from/(to) General Reserves	<u>(175)</u>	<u>(186)</u>
Balance at 30 September 2000	<u><u>4,194</u></u>	<u><u>3,343</u></u>
8 General Reserves		
Balance at 1 October 1999	(366)	(209)
Transfer from/(to) capital reserves	175	186
Surplus/(Deficit) for the year	<u>477</u>	<u>(343)</u>
Balance at 30 September 2000	<u><u>286</u></u>	<u><u>(366)</u></u>
9 Endowment fund		
a) Balance at 1 October 1999	375	360
Net Income during the year capitalized	<u>-</u>	<u>15</u>
Balance as at 30 September 2000	<u><u>375</u></u>	<u><u>375</u></u>
b) The endowment fund has been established with the aim of providing investment income to help defray a proportion of institutional costs. At 30 September 2000 the US\$ 375, 000 was on deposit in Deutsche Mark in Germany.		
10 Other funds		
a) This is made up as follows:		
HLM Fund	<u>77</u>	<u>77</u>
	<u><u>77</u></u>	<u><u>77</u></u>
b) The Health Learning Materials (HLM) fund is a deposit of proceeds in Kenya Shilling from the sale of part of printing equipment, the income of which has been set aside for production of health learning materials.		

	2000 US\$'000	1999 US\$'000
11 Provisions for liabilities and charges		
Aircraft Maintenance:		
Opening balance at 1 October, 1999	203	233
Additional provision during the year	<u>79</u>	<u>(30)</u>
At 30 September 2000	<u><u>282</u></u>	<u><u>203</u></u>

12 Fixed assets

a) Summary of movement of Fixed Assets

	Land & Buildings	Training centre Construction in Progress	Aircraft	Motor vehicles	Furniture, fittings & General equipment	Total
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Cost or valuation						
At 1 October 1999	822	1,312	1,515	211	962	4,822
Additions	-	977	-	14	35	1,026
Disposals	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(6)</u>	<u>(6)</u>
Cost/Valuation at 30 Sept 2000	<u>822</u>	<u>2,289</u>	<u>1,515</u>	<u>225</u>	<u>991</u>	<u>5,842</u>
Depreciation						
At 1 October 1999	236	-	351	202	690	1,479
Charge for the year	31	-	68	7	69	175
On disposals	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(6)</u>	<u>(6)</u>
At 30 September 2000	<u>267</u>	<u>-</u>	<u>419</u>	<u>209</u>	<u>753</u>	<u>1,648</u>
Net book amount						
At 30 September 2000	555	2,289	1,096	16	238	4,194
At 30 September 1999	586	1,312	1,164	9	272	3,343

b) Fixed assets which originally cost approximately US\$ 763,537 are fully depreciated but are still in use. If depreciation had been charged during the year on the cost of these assets the amount of fixed assets and capital funds would have been reduced by about US\$125,428.

	2000 US\$'000	1999 US\$'000
13 Investments		
Merc Finck and Co., Germany	375	375
ABN AMRO, Kenya	159	150
Merrill Lynch, USA	<u>890</u>	<u>-</u>
	<u>1,424</u>	<u>525</u>
14 Stocks and work in progress		
Aviation spare parts and work in progress	259	238
Printing materials and work in progress	25	43
BDU Books and manuals	69	99
Sundry stocks	<u>66</u>	<u>63</u>
	<u>419</u>	<u>443</u>
15 Debtors and Prepayments		
Trade Debtors	496	341
National Offices	28	42
Programme Advances	111	141
Staff Debtors	53	16
Others	<u>99</u>	<u>130</u>
	<u>787</u>	<u>670</u>
16 Cash and cash equivalents		
Cash at bank and in hand	896	1,574
Short term deposits	<u>1,504</u>	<u>1,463</u>
	<u>2,400</u>	<u>3,037</u>
For the purposes of the cash flow statement, the year-end cash and cash equivalents comprise the following:		
Cash and bank balance as above	2,400	3,037
Bank loan	<u>-</u>	<u>(47)</u>
	<u>2,400</u>	<u>2,990</u>
17 Creditors and other payables		
Trade payables	1,412	1,245
Accrued expenses	<u>704</u>	<u>518</u>
	<u>2,116</u>	<u>1,763</u>

18 Bank Overdraft

The Foundation has an overdraft facility of KShs 30 million (US\$400,000). The facility is secured by a floating debenture over the Foundation's fixed and moveable property.

19 Taxation

No taxation is provided in these accounts, as the Foundation is exempt from Kenyan taxation

20 Contingent liabilities

In the ordinary course of business the company has given guarantees amounting to \$81,000 (1999 \$ 100,000) to third parties.

21 Commitments

Capital commitments

Capital expenditure contracted for at the balance sheet date but not recognised in the financial statements is as follows:

	2000 US\$'000	1999 US\$'000
Property, plant and equipment	<u>589</u>	<u>1,000</u>

22 Trust Fund

The Trust Fund was constituted under a Trust Deed dated 6 November 1995 with its registered office in London. It has six Trustees of whom AMREF can nominate one. The principal activity of the trust is to raise funds to be held in an endowment fund to generate income to provide support for the work of AMREF for restricted lists of purposes that fall within the criteria outlined in the Trust Fund Deed.

The net assets of the fund according to audited accounts were US\$1,594,398 as at 30 September, 2000 (1999 US\$1,445,737)


23 Country of incorporation and registered office

The company is incorporated in Kenya under the Companies Act and domiciled in Kenya. The address of its registered office is:

Wilson Airport
P O Box 30125
Langata Road
NAIROBI


24 Currency

These financial statements are presented in US\$.




	1995/96	1996/97	1997/98	1998/99	1999/2000
—○— public grants	6.3	6.9	7.0	7.3	9.7
—△— private grants	6.1	4.2	5.6	7.1	7.1
—★— other funds	1.8	2.3	2.1	2.1	2.6
—●— total funds	14.2	13.4	14.7	16.5	19.4

all figures in US\$ million



	1995/96	1996/97	1997/98	1998/99	1999/2000
—✕— kenya	3.9	4.0	4.9	5.7	7.5
—●— uganda	1.8	1.7	2.4	2.1	3.0
—▲— regional	2.6	2.1	1.9	2.0	2.3
—○— tanzania	2.1	2.5	2.3	2.3	2.1
—★— mozambique	-	-	-	0.2	0.5
—●— somalia	0.4	0.5	0.5	0.5	0.5
—■— s. africa	0.3	0.2	0.3	0.4	0.3
—◆— ethiopia	-	-	0.1	0.1	0.2
—●— rwanda	0.6	0.7	0.2	0.1	0.1
—▲— headquarters	1.0	1.6	1.7	2.0	1.9
—■— capital	1.5	0.1	0.4	1.1	1.0
total expenditure	14.2	13.4	14.7	16.5	19.4

all figures in US\$ million



	1995/96	1996/97	1997/98	1998/99	1999/2000
health policy & systems reform	2.6	2.9	2.7	2.4	3.4
sexual & reproductive health	3.3	2.9	2.8	2.8	2.9
clinical services & emergency response	2.1	2.3	2.1	2.3	2.9
child adolescent health development	0.9	1.1	1.6	1.9	2.4
environmental health	0.6	0.6	1.3	1.6	1.8
aviation & emergency evacuation	0.8	1.0	1.1	1.2	1.7
headquarters & country offices	2.4	2.5	2.7	3.2	3.3
capital	1.5	0.1	0.4	1.1	1.0
total expenditure	14.2	13.4	14.7	16.5	19.4

all figures in US\$ million

	2000	1999
	US\$000	US\$000
Health Policy & Systems Reforms	3,425	2,347
Clinical Services & Emergency Responses	2,912	2,324
Sexual Reproductive Health	2,861	2,767
Child & Adolescent Health & Development	2,385	1,934
Environmental Health	1,752	1,550
Aviation & Emergency	1,664	1,233
	<hr/>	<hr/>
	14,999	12,155
	<hr/>	<hr/>
Staff Costs	1,872	1,778
Travel & Transport	343	395
Office Costs	744	637
Communications	178	228
Finance	209	206
	<hr/>	<hr/>
	3,346	3,244
	<hr/>	<hr/>
Total Operating Expenditure	18,345	15,399
Capital Expenditure	1,026	1,111
	<hr/>	<hr/>
Total Expenditure	<u>19,371</u>	<u>16,510</u>

	1995/96		1996/97		1997/98		1998/99		1999/2000	
	US\$	Percent	US\$	Percent	US\$	Percent	US\$	Percent	US\$	Percent
	000	%	000	%	000	%	000	%	000	%
USA	2,044	16.7%	1,841	16.6%	2,805	19.2%	1,751	13.8%	3,569	21.5%
UK	1,524	12.5%	1,486	13.4%	1,996	13.7%	2,411	18.9%	2,789	16.8%
Canada	1,201	9.8%	1,976	17.8%	1,446	9.9%	1,074	8.4%	1,455	8.8%
Sweden	602	4.9%	244	2.2%	2,018	13.8%	1,005	7.9%	1,426	8.6%
Ireland	23	0.2%	658	5.9%	830	5.7%	565	4.4%	1,058	6.4%
Netherlands	1,262	10.3%	1,004	9.1%	589	4.0%	1,140	9.0%	1,002	6.0%
Germany	1,386	11.3%	1,154	10.4%	1,361	9.3%	1,480	11.6%	795	4.8%
Spain					456	3.1%	563	4.4%	707	4.3%
Italy	83	0.7%	246	2.2%	408	2.8%	476	3.7%	703	4.2%
Kenya	1,092	8.9%	519	4.7%	609	4.2%	895	7.0%	519	3.1%
Tanzania	913	7.5%	381	3.4%	563	3.9%	469	3.7%	593	3.6%
International organisations	457	3.7%	489	4.4%	530	3.6%	250	2.0%	555	3.3%
Denmark	1,052	8.6%	204	1.9%	158	1.1%	211	1.7%	338	2.0%
Norway	311	2.6%	436	3.9%	460	3.1%	7	0.1%	278	1.7%
Austria	41	0.3%	14	0.1%	20	0.1%	192	1.5%	247	1.5%
Switzerland	97	0.8%	215	2.0%	141	1.0%	200	1.6%	199	1.2%
Uganda							14	0.1%	172	1.0%
South Africa	48	0.4%	14	0.1%	129	0.9%	16	0.1%	91	0.5%
Other countries	83	0.8%	207	1.9%	90	0.6%	8	0.1%	128	0.7%
Totals	12,219	100.0%	11,088	100.0%	14,609	100.0%	12,727	100.0%	16,624	100.0%

Source Country or organisation for grant funds received	Public Sector Funds US\$ 000	Private Agency Funds US\$ 000	Total Grant Income US\$ 000	1999/00 percent	1998/9 percent
USA	1,732	1,837	3,569	21.5%	13.8%
UK	1,363	1,426	2,789	16.8%	18.9%
Canada	1,356	99	1,455	8.8%	8.4%
Sweden	1,420	6	1,426	8.6%	7.9%
Ireland	1,058	0	1,058	6.4%	4.4%
Netherlands	32	970	1,002	6.0%	9.0%
Germany	537	258	795	4.8%	11.6%
Spain	0	707	707	4.3%	4.4%
Italy	0	703	703	4.2%	3.7%
Kenya	91	428	519	3.1%	7.0%
Tanzania	220	373	593	3.6%	3.7%
International Organizations	555	0	555	3.3%	2.0%
Denmark	338	0	338	2.0%	1.7%
Norway	278	0	278	1.7%	0.1%
Austria	159	88	247	1.5%	1.5%
Switzerland	13	186	199	1.2%	1.6%
Uganda	113	59	172	1.0%	0.1%
South Africa	0	91	91	0.5%	0.1%
Other Countries	0	128	128	0.7%	0.1%
Totals	9,265	7,359	16,624	100.0%	100.0%
1999/00 percentage	55.7%	44.3%	100.0%		
1998/99 percentage	53.8%	46.2%	100.0%		

FOUNDERS: Sir Archibald McIndoet, Dr Thomas D. Rees, Sir Michael Wood †

PATRONS: H.E. President Daniel T. Arap Moi, CGH, MP; HRH Prince Bernard of The Netherlands.

HEADQUARTERS

African Medical & Research Foundation, P.O. Box 30125, Nairobi. Tel: (+254 2) 501301, 500508.

E-mail: amrefinf@amref.org Telex: 23254 AMREF. Faxes: (+254 2) 609518 (main), 609522 (Finance & Administration)

Director General: John Batten

AUSTRIA

AMREF-Austria, Gesellschaft fuer Medizin und Forschung in Afrika e.V., inc. Flying Doctors Service, Waagplatz 3, A5020 Salzburg, Tel: +43 (0)662 840101. Fax: +43(0)662 847820. E-mail: amrefat@alpin.or.at, Chairman: Walter Schmidjell.

CANADA

AMREF-Canada, 489 College Street, Suite 407 Toronto, Ontario M6G 1A5 Tel: +1 (416) 961-6981. Fax: +1 (416) 961-6984. E-mail: amref@web.apc.org, Director: Bob Baines.

DENMARK

Den Afrikanske Lægefond, Gorrissen Federspiel Kierkegaard, 12 H.C. Andersens Boulevard, DK-1553, Copenhagen V. Tel: +45 33 41 41 41. Fax: +45 33 41 41 28. E-mail: tf@gfklaw.dk, Chairman: Thomas Federspiel.

ETHIOPIA

AMREF-Ethiopia, 227B Asmara Road, Worreda 18, Kabele 07, P.O. Box 20855, Addis Ababa. Tel: +251 1 531919 Ext 271. Fax: +251 1 534148. Director: Roma Hein.

GERMANY

AMREF, Gesellschaft für Medizin und Forschung in Africa e.V. Flying Doctor Services, Mauerkircher Str. 155, D-81925 München. Tel: +49 89 98 11 29. Fax: +49 89 98 11 89. E-mail: AMREFGermany@compuserve.com Chairman: Leonore Semler.

FRANCE

Association pour la Médecine et la Recherche en Afrique. 38 rue des Sablons 75116 Paris. Tel/Fax: +33 1 40 87 13 87; E-mail: amref france@hotmail.com; Directeur: Zarina de Bagneux.

ITALY

AMREF-Italia, Fondazione Africana per la Medicina e la Ricerca, Via Luigi Settembrini 30/00195, Roma. Tel: +39 06 320 22 22. Fax: +39 06 320 22 27. E-mail: amrefit@tin.it Director: Thomas Simmons.

Milan Office: Amref Eventi, Via Domenico Cirillo, 14, 20154 Milano. Tel/Fax: 39 02 345 1940.

KENYA

African Medical & Research Foundation, P.O. Box 30125, Nairobi. Tel: (+254 2) 501301, 500508. E-mail: amrefkco@africaonline.co.ke Faxes: 606340 (Administration), 336886 (Clinical), 502984 (Aviation). Director: Mette Kjaer

MOZAMBIQUE

AMREF Mozambique, Av. Angostinho Neto, 1584, P.O. Box 433, Maputo. Tel: 258 1 424 913; Fax: 258 1 310 810; E-mail: amrefmoz@tropical.co.mz; Country Representative: Lucas Omondi.

THE NETHERLANDS

Stichting AMREF-Nederland, Stevensbloem 269, 2331 JD Leiden. Tel: +31 71 576 94 76. Fax: +31 71 576 37 77. E-mail: amrefadm@bart.nl Executive Director: Constance van Haeften.

SOUTH AFRICA

AMREF-South Africa, P.O. Box 11489, The Tramshed, 0126, Pretoria; Tel: (+012) 320-1332/3; Fax: (+012) 320-1335. E-mail: amrefsa@iafrica.com Director: Blanche Pitt

SPAIN

Fundación AMREF-España, c/Ardemans 63, 1°280028 Madrid. Tel: +3491 564 6610 & 3491 563 5007. Fax: +3491 564 9534. E-mail: amref.espana@retemail.es Director: Ana Beekhof

SWEDEN

African Medical and Research Foundation, AMREF-Sweden, S-115 21 Stockholm, Sweden. e-mail: amref@bok.bonnier.se. Chairman: Helena Bonnier.

TANZANIA

AMREF, Ali Hassan Mwinyi Road, P.O. Box 2773, Dar es Salaam. Tel: +007 51-116610, Fax: +007 51-115823; E-mail: amreftz@africaonline.co.tz Director: Daraus Bukonya.

UGANDA

Uganda Country Office P.O. Box 10663 Kampala, Tel: (256-41) 250319/344579; Fax: (256-41) 344565; E-mail: amrefug@imul.com; Director: Peter Ngatia.

UNITED KINGDOM

African Medical and Research Foundation, UK 4 Grosvenor Place London SW1X 7HJ. Tel: +44 (020) 7201 6070. Fax: +44 (020) 7201 6170 E-mail: amref.uk@amref.org; Director: Alexander Héroys.

UNITED STATES OF AMERICA

African Medical & Research Foundation, Inc., 19 West 44th Street, Room 710, New York, NY 10036. Tel: +1 212 768 2440. Cables: AMREF USA NY. Fax: +1 212 768 4230. E-mail amrefusa@amrefusa.org. Director: Priscilla S. Goldfarb.

WEBSITE: www.amref.org

† deceased

AFRICAN MEDICAL AND RESEARCH FOUNDATION
(A Company Limited by Guarantee) (Incorporated in Kenya)